Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activations

Canadian Cancer Trials Group SC.24 - Phase II Randomized Feasibility Study Comparing Stereotactic Body Radiotherapy (SBRT) Versus Conventional Palliative Radiotherapy (CRT) for Patients with Spinal Metastases

Thanks go to everyone who helped get SC.24 up and running, particularly Alexander Montenegro-Suris for his work on the considerable RT and RTQA components of this study, Yvonne Murray for help and advice on the new e-QoL process, and IT who built the new infrastructure needed for this study.

SC.24 (along with HE.1) will be using a new and improved version of our RAdiotherapy Information SubmIssion Network (RAISIN) and will also be the first Canadian Cancer Trials Group trial to facilitate collection of patient-reported outcomes through direct patient entry on iPads using our brand new System for Patient Reported OUTcomes (SPROUT).


Canadian Cancer Trials Group HE.1 - Phase III Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases

Led by Dr. Laura Dawson at the Princess Margaret Cancer Centre, conduct of this trial is supported in part by a Quality of Life grant from the Canadian Cancer Society Research Institute.


Canadian Cancer Trials Group MA.36 (BIG 6-13) - A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multicenter Phase III Study to Assess the Efficacy and Safety of Olaparib versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy


SRC.7 (Alliance 091105) - A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)

For more information about these trials, please visit the trial-specific websites using this link ...